Ajanta Pharma Gears Up for Q3 Reveal on 30th January; Check Key Expectations Here
Click and Sign Up to Get Live Updates on Q3 Results
Updated: 29 Jan 2026 • 3:03 pm
Posted by:
Ajanta Pharma's Q3 results FY26 are scheduled to be announced on 30th January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.
Ajanta Pharma Q3 Results 2026 Preview
- Ajanta Pharma's revenue is expected to be in the range of ₹1,146.13 crore, a 3.41% YoY decrease.
- Profit After Tax, or PAT, is projected to rise by 7.58% YoY.
- Ajanta Pharma's EBITDA is expected to fall to ₹284.86 crore.
- Net profit is ₹232.88 crore, a rise 7.58% YoY
Ajanta Pharma Share Performance
- Over the past six months, Ajanta Pharma's share price has fallen by 4.31% to ₹2,701.50.
- Moreover, over the past year, the stock has increased by 2.83%.
- Despite this weak short-term performance, Ajanta Pharma's stock has delivered a financially sound 129.72% return over the past 5 years.
- As of 29th January 2026, the stock traded at ₹2,707.10 per share.
Key Factors to Watch for Ajanta Pharma Q3 Results FY26
- Revenue growth across segments – Trend in sales, especially branded generics performance in India, Asia and Africa, and US generics contribution.
- Profitability and margins – Movement in EBITDA and net profit margins amid cost pressures and forex impacts.
- Domestic branded generics momentum vs market – How India branded growth compares with overall Indian Pharmaceutical Market (IPM).
- Cost management – Trends in employee, R&D and other operating expenses that influence bottom-line quality.
- International expansion & strategic actions – Updates on global expansion (e.g., new subsidiary in Ireland) and product launches or regulatory approvals.
Final Thoughts
Ajanta Pharma will announce its Q3 FY26 results on 30th January 2026. Analysts expect 3.41% YoY revenue growth, a 7.58% rise in PAT, and a 5.81% fall in EBITDA. Ajanta Pharma focuses on branded generics growth across India, Asia and Africa, US generics performance, margins amid cost pressures, ANDA approvals/new launches, and geographic/therapy diversification efforts.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Recent Articles
Capital Small Finance Bank Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Carborundum Universal Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Capri Global Capital Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Digitide Solutions Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Flair Writing Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
GHCL Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Apar Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Apollo Pipes Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Recent Articles
Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
30 October 2026
Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
30 October 2026
Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
30 October 2026
Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
30 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
Asian Paints Share Price After Q2 Results: Profit Up 7%, but Price Hikes Are Yet to Brighten Margins
Popular this week
Borosil Share Price Jumps 16% After Strong Q2 Results: Record Profit, Margin Jump and Key Price Levels to Know
Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times